Application of POU2F1 activator in preparation of PD-L1PD-1 monoclonal antibody tumor immunotherapy drug

• Main Authors: YANG KAIYUN, WANG CHANG'AN, GAO CHANG'E, YANG XIN, ZHAO YUTAO, ZHANG MING, AHN YI-KYUN, WANG FENGTING, BAO MINGLIANG, CHEN NAN, YANG RUNXIANG, YANG CONGBO, YANG JIAPENG, LI MINGJIE, ZHOU JIE, YANG YINJU, DUAN HONGMIN, GUO GANG, CAI LIJUAN, YANG FANG, SHEN YUAN, ZHANG YING, YANG XIAOJUAN, LIN LING, SHUI TIEJUN, ZENG JIAJIA, WANG JIANKUI, DONG WEN
• Format: Patent
• Language: Chinese; English
• Published: 20.02.2024
• Subjects: BEER; BIOCHEMISTRY; CHEMISTRY; COMPOSITIONS OR TEST PAPERS THEREFOR; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL ORENZYMOLOGICAL PROCESSES; ENZYMOLOGY; HUMAN NECESSITIES; HYGIENE; INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIRCHEMICAL OR PHYSICAL PROPERTIES; MEASURING; MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEICACIDS OR MICROORGANISMS; MEDICAL OR VETERINARY SCIENCE; METALLURGY; MICROBIOLOGY; MUTATION OR GENETIC ENGINEERING; PHYSICS; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES; PROCESSES OF PREPARING SUCH COMPOSITIONS; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS; SPIRITS; TESTING; VINEGAR; WINE

The invention belongs to the technical field of biology, particularly relates to application of a POU2F1 activator in preparation of a PD-L1PD-1 monoclonal antibody tumor immunotherapy drug, and provides application of the POU2F1 activator in preparation of a PD-L1/PD-1 monoclonal antibody tumor immunotherapy drug. The PD-L1/PD-1 monoclonal antibody tumor immunotherapy drug is prepared by using a mechanism of targeted up-regulation of CRK by using a POU2F1 activator as a target site detection reagent. It is found that up-regulation of POU2F1 can directly regulate and control the tumor PD-L1 transcriptional level by up-regulation of a downstream transcription factor CRK, and therefore the tumor treatment effect of PD-1 monoclonal antibody blocking is enhanced. The mechanism directly discusses the existing problem of the action of the PD-1 blocking agent, and develops a new drug combination mode for providing a new research and development direction of PD-L1/PD-1 monoclonal antibody tumor immunodetection or imm